RO7515629

N/A

Report date: 2026/03/19 17:16:19

Base Information

Drug NameRO7515629

Drug Alias NameRO7515629RO-7515629RG-6353

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionHLA class I histocompatibility antigen, alpha chain G inhibitorsCD3 T-cell engagers

TargetsHLA class I histocompatibility antigen, alpha chain GT cell surface glycoprotein CD3

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsPancreatic Neoplasms +[5]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesF. Hoffmann-La Roche Ag

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesF. Hoffmann-La Roche Ltd

Active IndicationsN/A

Inactive IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsPancreatic Neoplasms +[5]

Other Information

ATC CodeN/A